Video

Dr. Colombo on Practice-Changing KEYNOTE-826 Data in Metastatic Cervical Cancer

Nicoletta Colombo, MD, PhD, discusses efficacy achieved with the addition of pembrolizumab to chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer. 

Nicoletta Colombo, MD, PhD, associate professor, obstetrics and gynecology, University of Milan-Bicocca, director, Ovarian Cancer Centre, chair, Program of Gynecology, European Institute of Oncology, discusses efficacy achieved with the addition of pembrolizumab (Keytruda) to chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer. 

The phase 3 KEYNOTE-826 trial (NCT03635567) examined the addition of pembrolizumab to chemotherapy with or without bevacizumab (Avastin) in this patient population and results demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS).

Immunotherapy and PD-1 inhibitors have previously shown efficacy as monotherapy in patients with metastatic cervical cancer, Colombo says. However, the KEYNOTE-826 study provided evidence that the combination of an anti–PD-1 agent and chemotherapy can improve OS and PFS compared with standard-of-care treatment, Colombo notes. This combination could represent a new standard of care for this population, and the data are practice changing, Colombo concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity